Oncolytics Biotech analyst rating shifts

On July 9, Oncolytics Biotech shares jumped about 16% after analysts offered divergent opinions on the stock’s rating. By July 30, the company’s share price moved only modestly, up 0.2% to $0.7530, with analysts split: Weiss upgraded the stock to a sell rating, HC Wainwright restated a buy, and Wall Street Zen downgraded it to sell. Market consensus remained a “moderate buy” with an average price target of $8.50. Oncolytics reported a quarterly loss of $0.08 per share, missing the $0.05 estimate, and analysts project a full‑year loss of $0.25 per share. Institutional investors added new stakes, including Renaissance Technologies ($608 k) and Citadel Advisors ($535 k).

The same session saw Oruka Therapeutics reach a 52‑week high of $98.44, closing at $97.86 on solid volume. Several analysts issued buy or overweight ratings, setting an average target of $134.30. Oruka posted a quarterly loss of $0.48 per share, beating the $0.52 consensus, while forecasting a full‑year loss of $2.06 per share. Insider activity included senior vice‑president Arjun Agarwal selling roughly 10,000 shares at an average price of $84.63.

Together, the snapshots illustrate ongoing volatility and mixed analyst sentiment for these biotech stocks.